CD19 and neoplasm: While this can yield a functional construct (or indeed constructs as we look at the multiple approved architectures containing the anti-CD19 binder FMC63; Table 1), this may not be optimal for CAR-T activity, phenotype and persistence, particularly as we move into more complex systems where tumor penetration and using targets that are not completely tumor specific become challenges.